This webinar describes current medication therapies for anxiety disorders and PTSD, focusing on FDA-approved and evidence-based approaches. Experimental drugs in development is reviewed, as well as the neurobiological rationale for their use. The risk/benefit profile and limitations of pharmacotherapies is discussed.
- To understand current trends in medication prescribing for the most common anxiety disorders and PTSD.
- To describe novel mechanisms of action of several medications in development for these conditions.
- To describe the recent FDA statement on the prescribing of benzodiazepines.